Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $13.00 Average Target Price from Brokerages

Compass Therapeutics, Inc. (NASDAQ:CMPX) has been given an average recommendation of “Moderate Buy” by the fifteen brokerages that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, thirteen have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $13.00.

CMPX has been the subject of a number of analyst reports. Jefferies Financial Group reiterated a “buy” rating and issued a $9.00 target price on shares of Compass Therapeutics in a research note on Thursday, March 5th. Craig Hallum initiated coverage on shares of Compass Therapeutics in a research note on Friday, February 13th. They set a “buy” rating and a $15.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Therapeutics in a report on Wednesday, January 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Compass Therapeutics in a research note on Thursday, March 12th. Finally, Citizens Jmp set a $10.00 target price on shares of Compass Therapeutics in a research report on Wednesday, December 3rd.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Vivo Capital LLC boosted its position in Compass Therapeutics by 70.0% during the second quarter. Vivo Capital LLC now owns 6,043,466 shares of the company’s stock worth $15,713,000 after purchasing an additional 2,487,443 shares during the period. Suvretta Capital Management LLC raised its position in shares of Compass Therapeutics by 97.2% in the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock valued at $49,354,000 after purchasing an additional 6,951,666 shares during the period. Monashee Investment Management LLC lifted its stake in shares of Compass Therapeutics by 657.6% in the third quarter. Monashee Investment Management LLC now owns 1,250,000 shares of the company’s stock worth $4,375,000 after buying an additional 1,085,000 shares during the last quarter. CM Management LLC acquired a new stake in shares of Compass Therapeutics in the third quarter worth $525,000. Finally, Tema Etfs LLC bought a new stake in shares of Compass Therapeutics during the 4th quarter worth $538,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Price Performance

Shares of CMPX stock opened at $5.15 on Wednesday. Compass Therapeutics has a fifty-two week low of $1.33 and a fifty-two week high of $6.88. The stock’s 50-day moving average is $5.92 and its two-hundred day moving average is $4.95. The firm has a market cap of $927.46 million, a P/E ratio of -11.98 and a beta of 1.48.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. As a group, research analysts expect that Compass Therapeutics will post -0.36 EPS for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.